Biogen (NASDAQ:BIIB) Competitive Risks Growing in 2011

Barclays (NYSE:BCS) sees the competitive risks growing for Biogen (NASDAQ:BIIB) in 2011, and the thing to watch will be whether or not IMPACT RX trends will be sustainable.

Barclays said, "We are maintaining our Equal Weight rating on BIIB following review on IMPACT RX data for competitor Gilenya and in consideration of increasing competitive risk in 2011. With strong launch of Gilenya masked by aggressive Novartis (NYSE:NVS) sampling we see potentially greater downside risk to Avonex and Tysabri trends for BIIB than suggested by IMS prescription data. Sustainability of IMPACT RX trends will be key to watch in 2011."

Barclays maintains an "Equalweight" on Biogen, which closed Friday at $68.14, up $0.22, or 0.32 percent. They have a price target of $53 on them.